Revenue increased from 26,291 million yen in 26\/3 Q2 to 28,735 million yen in 27\/3 Q2, a Year-over-Year increase of 9.3%. EBITDA decreased from 3,713 million yen to 3,121 million yen. By segment, expansion of domestic medical institutions contributed positively, while margins were pressured by unit price declines in hospice and upfront investments overseas. The full-year forecast plans revenue of 64,600 million yen with progress at 44.5%; full-year EBITDA is planned at 9,700 million yen, with progress of 32.2% as of Q2, indicating some delay. However, improvements are expected in the second half.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"9158","jir_company_name":"CUC Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-29","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/9158-20261029-02.pdf","jir_short_summary":"Revenue increased from 26,291 million yen in 26\/3 Q2 to 28,735 million yen in 27\/3 Q2, a Year-over-Year increase of 9.3%. EBITDA decreased from 3,713 million yen to 3,121 million yen. By segment, expansion of domestic medical institutions contributed positively, while margins were pressured by unit price declines in hospice and upfront investments overseas. The full-year forecast plans revenue of 64,600 million yen with progress at 44.5%; full-year EBITDA is planned at 9,700 million yen, with progress of 32.2% as of Q2, indicating some delay. However, improvements are expected in the second half.","jir_summary":"### Performance Overview\nConsolidated revenue expanded steadily. Growth was driven by expansion of domestic medical institutions and increased use of home-visit nursing, while EBITDA declined due to unit price decreases in hospice services and upfront investments overseas. On a quarterly basis, revenue reached historically high levels, but overall profit levels fell short of plan in some areas.\n\n### Outlook and Challenges\nFor the second half, domestic medical institutions are expected to drive revenue and profit growth through expansion of supported sites, while downside trends in overseas patient numbers and OBL investment costs will continue. Hospices aim to recover through improved occupancy at new facilities and cost containment. Home-visit nursing and medical care residences will continue strengthening sales and operations to improve utilization. Full-year progress is somewhat behind plan, but improvements in the second half are assumed.","jir_financial_highlights":"Revenue: 28,735 (YoY +9.3%)\nEBITDA: 3,121 (Year-over-Year (decrease))\nNet Income Attributable to Owners of Parent: -101 (Previous year same period: 612)","jir_category":"","jir_hashtags":"#CUC, #Earnings, #BusinessSegments, #MediumTermPlan","jir_key_figures":"Revenue: 64,600 million yen (plan) \u2192 27\/3 Q2 actual: 28,735 million yen (progress 44.5%)\nEBITDA: 9,700 million yen (plan) \u2192 27\/3 Q2 actual: 3,121 million yen (progress 32.2%)\nNet Income Attributable to Owners of Parent: 1,100 million yen (plan) \u2192 27\/3 Q2 actual: (101) million yen","jir_meta_title":"CUC Inc. Fiscal Year Ending March 2027 Q2 Earnings Presentation | Revenue Growth and Second-Half Outlook","jir_meta_description":"CUC Inc.'s Q2 FY2027 earnings presentation. Revenue rose Year-over-Year while EBITDA declined. Explains impact from domestic medical institution expansion and overseas investments, and outlines expected second-half improvements. Includes segment trends and full-year progress.","jir_og_title":"CUC Inc. Earnings Presentation: Q2 FY2027 Performance Trends","jir_og_description":"CUC Inc. earnings presentation. Revenue increased while EBITDA decreased. Reviews domestic expansion, overseas investment impacts, and outlook for second-half improvement. Covers segment trends and full-year progress.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"[{x:'26\/3 Q2',y:26291},{x:'27\/3 Q2',y:28735}]\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Profit Trend\", \"jir_chart_json_data\": \"[{x:'26\/3 Q2',y:1711},{x:'27\/3 Q2',y:947}]\"}, {\"jir_chart_id\": \"ebitda_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"EBITDA Trend\", \"jir_chart_json_data\": \"[{x:'26\/3 Q2',y:3713},{x:'27\/3 Q2',y:3121}]\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Revenue Breakdown\", \"jir_chart_json_data\": \"[{segment:'Domestic Medical Institutions',value:4842},{segment:'Home-Visit Nursing',value:6484},{segment:'Hospice',value:7936}]\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"EBITDA Margin Analysis\", \"jir_chart_json_data\": \"[{segment:'Domestic',value:3713},{segment:'Overseas',value:(-339)}]\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Comparison of Full-Year Guidance and Results\", \"jir_chart_json_data\": \"[{x:'26\/3',y:44.5},{x:'27\/3',y:44.5}]\"}]","ir_related_company":57503,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-136686","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n